Welcome to our dedicated page for E Therapeutics news (Ticker: ETXPF), a resource for investors and traders seeking the latest updates and insights on E Therapeutics stock.
ETXPF is associated with e-therapeutics plc, a biotechnology company that has announced a corporate relaunch as Tangram Therapeutics. Company news describes this business as uniting computation, RNA interference (RNAi), and proprietary chemistry to develop GalOmic siRNA medicines for diseases with high unmet need. The news flow around ETXPF therefore provides insight into both the historical e-therapeutics narrative and the more recent Tangram Therapeutics identity.
News items for this company highlight several themes. Updates describe progress in its GalOmic pipeline, including ETX-312 (also referred to as TGM-312) for metabolic dysfunction-associated steatohepatitis (MASH), ETX-148 (also referred to as TGM-148) for bleeding disorders, and ETX-407 for dry age-related macular degeneration. Releases have detailed preclinical and toxicology data, IND- or CTA-enabling studies, and the company’s stated plans for regulatory submissions as programs approach the clinic.
Other articles focus on the company’s computational and AI platforms. As e-therapeutics, it reported advances in its HepNet platform and described work with cloud providers to enhance generative AI capabilities. With the Tangram Therapeutics relaunch, news coverage introduces LLibra OS, a next-generation applied AI platform built on HepNet’s foundations, designed to integrate diverse datasets and support target identification and GalOmic siRNA design.
Investors and observers using this news page can review company communications on pipeline milestones, scientific presentations, platform enhancements, business updates, and financing events such as share subscriptions. Because the company has described a transition from e-therapeutics plc to Tangram Therapeutics, this news archive is useful for understanding how its RNAi and AI strategies have evolved over time.
Tangram Therapeutics (OTC:ETXPF), formerly e-therapeutics, has announced a strategic corporate relaunch and unveiled its next-generation AI platform, LLibra OS. The company, focused on RNA interference (RNAi) medicines, is advancing toward its first Clinical Trial Application (CTA) submission in Q4 2025.
The company's pipeline includes TGM-312 for metabolic dysfunction-associated steatohepatitis (MASH) and TGM-148 for bleeding disorders, with the latter planned for regulatory submission in 2026. LLibra OS, built on the foundations of HepNet, combines AI capabilities to identify novel targets, evaluate therapeutic potential, and design GalOmic siRNA medicines.
e-therapeutics (OTCQX:ETXPF) has announced significant progress in de-risking its lead candidate ETX-312, a GalOmic siRNA therapy for metabolic dysfunction-associated steatohepatitis (MASH). The company has achieved two major milestones: successful completion of GLP-compliant toxicology studies showing excellent tolerability at high doses, and GMP manufacturing of the clinical trial batch.
The toxicology studies demonstrated that ETX-312 was well tolerated across all dose levels, with no toxicity or adverse findings, supporting a broad therapeutic window. The company remains on track for Clinical Trial Application (CTA) submission in Q4 2025, with productive regulatory interactions supporting their clinical strategy.
e-therapeutics announced new preclinical results for ETX-312, their GalOmic siRNA candidate for treating metabolic dysfunction-associated steatohepatitis (MASH), to be presented at EASL Congress 2025. The study using the Gubra-Amylin NASH diet-induced obese mouse model showed that ETX-312 achieved:
- Significant improvements in NAFLD Activity Score (NAS), both as monotherapy and in combination therapy - All mice on combination therapy achieved ≥2-point NAS reductions, with up to 5-point improvements - Comparable fibrosis progression slowdown to GLP-1/GIP receptor agonist or FGF-21 analogue controls - Statistically significant reductions in hepatic collagen staining and biomarkers TIMP-1 and PIIINP
The company remains on track for regulatory submission by end of 2025, with ETX-312 currently in IND-enabling studies.
e-therapeutics has announced plans to present new preclinical data for ETX-148 at the Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) in February 2025. The presentation will showcase the efficacy and safety results of ETX-148 in murine models of haemophilia A and B. ETX-148, which is being developed for treating bleeding disorders, is currently in IND-enabling studies, with an IND submission planned for 2026.
The oral presentation, numbered OR10, will take place during the SLAM session on February 7th, 2025, at EAHAD 2025, which runs from February 4th to 7th.
e-therapeutics reported interim results and business updates for H1 2024. The company continues advancing its GalOmic pipeline, with ETX-312 progressing through IND-enabling studies for MASH treatment, targeting submission in 2025. The company strengthened its leadership team and infrastructure, partnering with AWS to enhance AI capabilities. Financial highlights include a cash position of £41.0 million as of July 31, 2024, following a £28.9 million fundraise. Operating loss increased to £7.5 million, with R&D expenses at £5.6 million and G&A costs at £2.0 million. The company maintains 39 employees.
e-therapeutics plc (OTC-QX: ETXPF) announced a £13.5 million fundraise through a subscription for ordinary shares at 20p each, managed by M&G Investment Management. This subscription, representing 13.12% of existing capital, will facilitate growth initiatives including expanding their RNAi drug pipeline and developing computational tools. A premium of 12% over the previous closing price was achieved. The issuance is subject to shares being admitted by October 6, 2022. The CEO highlighted the potential of RNAi-based therapies in drug discovery.